{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T20:14:41Z","timestamp":1795032881687,"version":"4.10.2"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.ygyno.2025.03.018","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T11:29:19Z","timestamp":1742988559000},"page":"192-199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["ENGOT-OV16\/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety"],"prefix":"10.1016","volume":"195","author":[{"given":"Ursula A.","family":"Matulonis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rn","family":"Herrstedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Oza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Mahner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Redondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Berton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan S.","family":"Berek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte A.","family":"Haslund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Marm\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gonz\u00e1lez-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"B\u00e9court","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna V.","family":"Tinker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"Ledermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedict","family":"Benigno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Lindahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izabela A.","family":"Malinowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjinder","family":"Bains","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley J.","family":"Monk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansoor R.","family":"Mirza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2025.03.018_bb0005","doi-asserted-by":"crossref","unstructured":"H. Sung, J. Ferlay, R.L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal, et al., Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin. 71 (2021) 209\u2013249, https:\/\/doi.org\/10.3322\/caac.21660.","DOI":"10.3322\/caac.21660"},{"key":"10.1016\/j.ygyno.2025.03.018_bb0010","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.61","article-title":"Ovarian cancer","volume":"2","author":"Matulonis","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ygyno.2025.03.018_bb0015","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","article-title":"Homologous recombination deficiency: Exploiting the fundamental vulnerability of ovarian cancer","volume":"5","author":"Konstantinopoulos","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ygyno.2025.03.018_bb0020","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1093\/annonc\/mds203","article-title":"The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane\/platinum-based therapy","volume":"23","author":"Hanker","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2025.03.018_bb0025","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00404-021-06070-2","article-title":"Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors as maintenance therapy in women with newly diagnosed ovarian cancer: a systematic review and meta-analysis","volume":"304","author":"Cheng","year":"2021","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.ygyno.2025.03.018_bb0030","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1158\/1078-0432.CCR-18-0042","article-title":"FDA approval summary: Niraparib for the maintenance treatment of patients with recurrent ovarian cancer in response to platinum-based chemotherapy","volume":"24","author":"Ison","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2025.03.018_bb0045","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2025.03.018_bb0050","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S1470-2045(18)30333-4","article-title":"Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16\/NOVA): Results from a double-blind, phase 3, randomised controlled trial","volume":"19","author":"Oza","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2025.03.018_bb0055","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1200\/JCO.19.00917","article-title":"Niraparib maintenance treatment improves time without symptoms or toxicity (TWiST) versus routine surveillance in recurrent ovarian cancer: A TWiST analysis of the ENGOT-OV16\/NOVA trial","volume":"37","author":"Matulonis","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.03.018_bb0060","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/S0090-8258(21)00693-4","article-title":"Long-term safety and secondary efficacy endpoints in the ENGOT-OV16\/NOVA phase III trial of niraparib in recurrent ovarian cancer","volume":"162","author":"Matulonis","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.03.018_bb0065","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1002\/sim.6591","article-title":"A versatile test for equality of two survival functions based on weighted differences of Kaplan-Meier curves","volume":"34","author":"Uno","year":"2015","journal-title":"Stat. Med."},{"key":"10.1016\/j.ygyno.2025.03.018_bb0070","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/biom.12384","article-title":"On the restricted mean survival time curve in survival analysis","volume":"72","author":"Zhao","year":"2016","journal-title":"Biometrics"},{"key":"10.1016\/j.ygyno.2025.03.018_bb0075","doi-asserted-by":"crossref","first-page":"A226","DOI":"10.1136\/ijgc-2022-ESGO.488","article-title":"2022-RA-249-ESGO Overall survival results from ARIEL3: A phase 3 randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma","volume":"32","author":"Coleman","year":"2022","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2025.03.018_bb0080","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1002\/cncr.29082","article-title":"Intermediate clinical endpoints: A bridge between progression-free survival and overall survival in ovarian cancer trials","volume":"121","author":"Matulonis","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2025.03.018_bb0085","author":"European Medicines Agency"},{"issue":"suppl","key":"10.1016\/j.ygyno.2025.03.018_bb0090","doi-asserted-by":"crossref","first-page":"5578","DOI":"10.1200\/JCO.2023.41.16_suppl.5578","article-title":"Response to subsequent platinum-based chemotherapy post PARP inhibitor in recurrent epithelial ovarian cancer","volume":"41","author":"Vacheresse","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.03.018_bb0095","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): A final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2025.03.018_bb0100","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1002\/cncr.29995","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy","volume":"122","author":"Matulonis","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2025.03.018_bb0105","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2025.03.018_bb0110","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1136\/ijgc-2023-004478","article-title":"Overall survival after PARP maintenance treatment in platinum-sensitive relapsed ovarian cancer: Opposing views of the US Food and Drug Administration and European Medicines Agency","volume":"33","author":"Monk","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2025.03.018_bb0115","unstructured":"N. Howlader, A. Noone, M. Krapcho, D. Miller, A. Brest, M. Yu, et al., SEER cancer statistics review, 1975\u20132017, National Cancer Institute. https:\/\/seer.cancer.gov\/csr\/1975_2017\/."},{"key":"10.1016\/j.ygyno.2025.03.018_bb0120","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ygyno.2020.09.006","article-title":"Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16\/NOVA trial","volume":"159","author":"Mirza","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.03.018_bb0125","doi-asserted-by":"crossref","first-page":"A3","DOI":"10.1136\/ijgc-2022-ESGO.488","article-title":"O003\/#557\u202fOverall survival results from ARIEL3: a phase 3 randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma","volume":"32","author":"Coleman","year":"2022","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2025.03.018_bb0130","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.ygyno.2022.08.021","article-title":"Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma","volume":"167","author":"O'Malley","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.03.018_bb0135","doi-asserted-by":"crossref","first-page":"6002","DOI":"10.1200\/JCO.2020.38.15_suppl.6002","article-title":"Final overall survival (OS) results from SOLO2\/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation","volume":"38","author":"Poveda","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.03.018_bb0140","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ygyno.2018.10.013","article-title":"The impact of new drugs for breast and ovarian cancer on the occurrence of therapy-related myeloid neoplasms: Understanding the baseline incidence","volume":"151","author":"Sella","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.03.018_bb0145","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonzalez-Martin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2025.03.018_bb0150","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2025.03.018_bb0155","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2025.03.018_bb0160","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(16)30376-X","article-title":"Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: An updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial","volume":"17","author":"Ledermann","year":"2016","journal-title":"Lancet Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825000873?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825000873?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T13:24:18Z","timestamp":1777641858000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825825000873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":30,"alternative-id":["S0090825825000873"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.03.018","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ENGOT-OV16\/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}